EP0934305A4 - Integrin antagonists - Google Patents

Integrin antagonists

Info

Publication number
EP0934305A4
EP0934305A4 EP97938568A EP97938568A EP0934305A4 EP 0934305 A4 EP0934305 A4 EP 0934305A4 EP 97938568 A EP97938568 A EP 97938568A EP 97938568 A EP97938568 A EP 97938568A EP 0934305 A4 EP0934305 A4 EP 0934305A4
Authority
EP
European Patent Office
Prior art keywords
integrin antagonists
integrin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938568A
Other languages
German (de)
French (fr)
Other versions
EP0934305A1 (en
Inventor
Mark E Duggan
George D Hartman
William F Hoffman
Robert S Meissner
James J Perkins
Ben C Askew
Paul J Coleman
John H Hutchinson
Adel M Naylor-Olsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703015.9A external-priority patent/GB9703015D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0934305A1 publication Critical patent/EP0934305A1/en
Publication of EP0934305A4 publication Critical patent/EP0934305A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP97938568A 1996-08-29 1997-08-25 Integrin antagonists Withdrawn EP0934305A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2512396P 1996-08-29 1996-08-29
US25123P 1996-08-29
US3357996P 1996-12-19 1996-12-19
US33579P 1996-12-19
GB9703015 1997-02-13
GBGB9703015.9A GB9703015D0 (en) 1997-02-13 1997-02-13 Alpha v B3 antagonists
US4717797P 1997-05-20 1997-05-20
US47177P 1997-05-20
PCT/US1997/014912 WO1998008840A1 (en) 1996-08-29 1997-08-25 Integrin antagonists

Publications (2)

Publication Number Publication Date
EP0934305A1 EP0934305A1 (en) 1999-08-11
EP0934305A4 true EP0934305A4 (en) 2001-04-11

Family

ID=27451604

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938568A Withdrawn EP0934305A4 (en) 1996-08-29 1997-08-25 Integrin antagonists

Country Status (5)

Country Link
EP (1) EP0934305A4 (en)
JP (1) JP2002511052A (en)
AU (1) AU724191B2 (en)
CA (1) CA2263999A1 (en)
WO (1) WO1998008840A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) * 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
ES2381591T3 (en) 1998-04-09 2012-05-29 Meiji Seika Pharma Co., Ltd. Aminopiperidine derivatives as alpha v beta 3 integrin antagonists
PL343406A1 (en) * 1998-04-10 2001-08-13 Searle & Co Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
US6689754B1 (en) 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
AU3561099A (en) * 1998-04-14 1999-11-01 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
AU3817899A (en) * 1998-04-15 1999-11-01 Inserm Therapy of atherosclerosis
ATE461210T1 (en) * 1998-06-11 2010-04-15 Ortho Mcneil Pharm Inc PYRAZINE PROTEASE INHIBITORS
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
EP0997474B1 (en) * 1998-08-14 2003-10-29 Pfizer Inc. Antithrombotic agents
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co LACTAM INHIBITORS OF FXa AND METHOD
CA2368049A1 (en) 1999-04-13 2000-10-19 Basf Aktiengesellschaft Integrin receptor ligands
RO121640B1 (en) * 1999-05-07 2008-01-30 Texas Biotechnology Corporation Propionic acid derivatives inhibiting integrins binding to receptors thereof, pharmaceutical composition containing the same and use thereof
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
WO2000072801A2 (en) 1999-06-02 2000-12-07 Merck & Co., Inc. Alpha v integrin receptor antagonists
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
WO2001005772A1 (en) 1999-07-19 2001-01-25 Merck Frosst Canada & Co. Pyrazinones, compositions containing such compounds
EP1209152A4 (en) 1999-08-05 2003-03-12 Meiji Seika Kaisha Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alpha v beta 3 antagonism
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc Integrin receptor antagonists
JP2003511355A (en) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト Endothelin signaling pathway inhibitors and αvβ3 receptor antagonists for combination therapy
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
ATE289299T1 (en) 2000-04-05 2005-03-15 Pharmacia Corp POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USABLE FOR SELECTIVE INHIBITION OF THE COAGULATION PROCESS
CA2405306A1 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
AU2001253363A1 (en) 2000-04-17 2001-10-30 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
JP2004517074A (en) 2000-11-20 2004-06-10 ファルマシア・コーポレーション Substituted polycyclic aryl and heteroaryl pyridines useful for selectively inhibiting the coagulation cascade
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
CN1247258C (en) 2001-04-24 2006-03-29 默克专利有限公司 Combination therapy using anti-angiogenic agents and tnfa
CA2460149A1 (en) 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
WO2003029216A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
MXPA04003170A (en) 2001-10-03 2004-07-08 Pharmacia Corp Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade.
US20030171368A1 (en) * 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
AU2006255009B2 (en) * 2005-06-07 2011-10-27 Pharmacopeia L.L.C. Azinone and diazinone V3 inhibitors for depression and stress disorders
EP1973569B1 (en) 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
JP2012528079A (en) 2009-05-25 2012-11-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Continuous administration of integrin ligand to treat cancer
HUE063437T2 (en) 2013-09-24 2024-01-28 Fujifilm Corp Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CR20210109A (en) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBITING av ß6 INTEGRIN
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995014683A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014682A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995018111A1 (en) * 1993-12-28 1995-07-06 The Du Pont Merck Pharmaceutical Company Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5534524A (en) * 1994-05-09 1996-07-09 Board Of Regents, The University Of Texas System Suppression of bone resorption by quinolines
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995014683A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014682A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995018111A1 (en) * 1993-12-28 1995-07-06 The Du Pont Merck Pharmaceutical Company Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1995032710A1 (en) * 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO9808840A1 *
WITYAK,J. ET AL.: "Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor Antagonists", J.MED.CHEM., vol. 40, no. 1, 3 January 1997 (1997-01-03), WASHINGTON, pages 50 - 60, XP002158237 *
XUE,C.B. ET AL.: "Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists", J.MED.CHEM., vol. 40, no. 13, 20 June 1997 (1997-06-20), WASHINGTON, pages 2064.2084, XP002158238 *

Also Published As

Publication number Publication date
CA2263999A1 (en) 1998-03-05
EP0934305A1 (en) 1999-08-11
AU4086597A (en) 1998-03-19
AU724191B2 (en) 2000-09-14
WO1998008840A1 (en) 1998-03-05
JP2002511052A (en) 2002-04-09

Similar Documents

Publication Publication Date Title
EP0934305A4 (en) Integrin antagonists
EP0946164A4 (en) Integrin antagonists
EP1007026A4 (en) Integrin antagonists
EP1047425A4 (en) Integrin receptor antagonists
AU3213799A (en) Integrin antagonists
EP0912175A4 (en) Fibrinogen receptor antagonists
EP1100506A4 (en) Integrin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
HU9603082D0 (en) Neurokinine (tachykinine) antagonists
EP1105389A4 (en) Integrin receptor antagonists
IL128409A0 (en) Muscarinic antagonists
EP1007051A4 (en) Integrin receptor antagonists
EP0880511A4 (en) Integrin receptor antagonists
EP0913191A4 (en) Microemulsion
EP0885205A4 (en) Fibrinogen receptor antagonists
HU9601176D0 (en) Adhesion-receptor antagonists
EP0885213A4 (en) Fibrinogen receptor antagonists
IL134175A0 (en) Endothelin antagonists
EP1027337A4 (en) Integrin receptor antagonists
HU9503191D0 (en) Adhesion-receptor antagonists
ZA98256B (en) Tachykinin antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
ZA985209B (en) Endothelin antagonists
GB9724656D0 (en) Local oscillator arrangement
GB9616786D0 (en) Catch

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990329

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010228

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040330